Bolt Biotherapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Bolt Biotherapeutics Inc's ROI in the second quarter of 2026?
Bolt Biotherapeutics Inc recorded a cumulative net loss of $-29 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -65.11%.

Within the Healthcare sector 332 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3102 to 3750.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-43.98 %	-40.07 %	-40.23 %	-39.74 %	-40.35 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	32	41	48	55	68
Return On Investment (TTM)	-65.11 %	-55.83 %	-54.82 %	-61.19 %	-64.36 %
BOLT's Overall Ranking	# 3750	# 3102	# 2823	# 3304	#
Seq. Investment Change TTM	-16.69 %	-12.98 %	-12.71 %	-11.47 %	-10.87 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-29	-30	-33	-43	-51

BOLT Company Profile >> Back to BOLT Roi Comparisons >> See Annual BOLT Return On Investment

Return On Investment BOLT's Ranking
Within:	No.
Industry	# 135
Sector	# 333
Overall	# 3750

Return On Investment Statistics
High	Average	Low
13.06 %	-31.86 %	-71.66 %
(Mar 31 2014)		(Mar 31 2025)

News about Bolt Biotherapeutics Inc Return on Investment ROI

Advancements in Cancer Immunotherapy Insights from Bolt Biotherapeutics BDC-4182 and BDC-1001

November 7, 2024

: Recent advancements in the realm of immunotherapy have showcased significant potential in battling cancer due to innovative approaches that harness the immune system. This article delves into the promising preclinical data for BDC-4182 presented by Bolt Biotherapeutics, alongside crucial findings from the Phase 1 dose-escalation trial of BDC-1001 at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). These developments highlight the efficacy and safety of these therapeutic agents, underscoring their potential applications in clinical settings. Cancer remains one of the leading causes of death globally, prompting ongoing research into effective treatment modalities. Immunotherapy has emerged as a game-changing approach, exploiting the body’s immune system to target and eliminate tumor cells. Bolt Biotherapeutics is a key player in this field, focusing on novel biotherapeutic agents designed to enhance anti-tumor responses through immune modulation. This article provides an overview of the latest findings related to BDC-4182’s preclinical performance and insights from the BDC-1001 clinical trial, contributing vital information to the evolving landscape of cancer treatment.

Navigating Legal Turbulence The Impact of Securities Class Action on Bolt Biotherapeutics,

August 14, 2024

Navigating Legal Waters: The Bolt Biotherapeutics Securities Class Action and Its Implications In recent news, Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), a clinical-stage immuno-oncology company, has found itself at the center of a securities class action lawsuit. The Rosen Law Firm, known for its expertise in investor rights, has actively encouraged investors who purchased Bolt’s securities between February 5, 2021, and May 14, 2024, to take legal action before the looming September 3, 2024, lead plaintiff deadline. This article assesses the facts of the case, the basis for the lawsuit, and its potential impacts on Bolt Biotherapeutics. The Case at Hand The class action lawsuit targets Bolt Biotherapeutics for alleged violations of federal securities laws. While specific details of the allegations are not expanded upon in the press release, typical claims in such lawsuits often involve accusations of misleading statements or omissions that may have resulted in financial losses for investors. By setting a class period from early 2021 to mid-2024, the lawsuit suggests that the alleged misconduct spanned over three years, implicating significant company activities during this time.

Financial Statements
Bolt Biotherapeutics Inc's II. Quarter Investments	$ 32 Millions	BOLT's Balance sheet
Bolt Biotherapeutics Inc's II. Quarter Income	$ -8 Millions	Quarterly BOLT's Income Statement
BOLT's Income by Division		See BOLT's Income by Division

BOLT Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	48	84	139	205	286
Y / Y Investment Growth	-42.33 %	-39.87 %	-31.93 %	-28.53 %	284.08 %
Net Income in Millions	-33	-63	-69	-88	-99
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-69.08 %	-75.34 %	-49.66 %	-43.04 %	-34.43 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
BOLT's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for BOLT's Competitors
Subscribers only: Roi for Bolt Biotherapeutics Inc's Suppliers
Subscribers only: Return On Investment for BOLT's Customers

Other Ratios
BOLT's Roa	BOLT's Inventory Turnover Ratio	BOLT's Growth Rates	BOLT's Dividend Statistics
	BOLT's Profitability Ratios	BOLT's Asset Turnover Ratio	BOLT's Dividend Growth
BOLT's Roe	BOLT's Valuation Ratios	BOLT's Financial Strength Ratios	BOLT's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-05T00:02:13+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.